UK-based contract research organisation (CRO) QED Clinical Services has widened its global coverage by setting up a wholly owned subsidiary in Ahmedabad, India.
The new subsidiary, QED Clinical Services India Private Limited, will add operational and therapeutic expertise to the QED mix while expanding the CRO’s capacity and capability to deliver high-quality, cost-effective projects on a global scale, it said.
Heading up the Indian business is country head and director of operations Ali Sajjad Bohra, who has extensive leadership experience in clinical monitoring, functional services and project management across major Asia Pacific markets such as India, Japan, South Korea and Australia.
India and the Asia Pacific region will remain key markets for drug development “on account of a variety of benefits”, he commented.
“With our in-depth experience and knowledge of the region, we are committed to provide customised, cost-efficient and high-quality services to both global as well as local clients.”
